Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02355743 · ClinicalTrials.gov registry record · Phase 4
rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome
A Phase 4 study of Short Bowel Syndrome, sponsored by Lynn Malec.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02355743 is a Phase 4 study of Short Bowel Syndrome that has completed, run by Lynn Malec. The registered enrollment target is 8 participants, below the 184-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02355743, a Phase 4 study of Short Bowel Syndrome, has completed, sponsored by Lynn Malec.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary research question is, in patients with short bowel syndrome requiring central venous access device (CVAD) for long-term total parenteral nutrition, is once weekly recombinant tissue plasminogen activator (rtPA) lock therapy more effective than routine care using heparin flushes in reducing the incidence of line-associated thrombosis and infection.
Conditions Studied
Interventions
- DRUG rtPA lock therapy
Study Locations (1)
Pennsylvania
- Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2016-09-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02355743
The ClinicalTrials.gov registry entry for NCT02355743 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (96% lower). The listed sponsor is Lynn Malec, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which rtPA lock therapy is the first listed.
NCT02355743 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02355743 about?
NCT02355743 is a clinical study titled "rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome". The primary research question is, in patients with short bowel syndrome requiring central venous access device (CVAD) for long-term total parenteral nutrition, is once weekly recombinant tissue plasminogen activator (rtPA) lock therapy more effective than routine care using heparin flushes in reduci...
What is the current status of trial NCT02355743?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2015-02-01. Estimated completion is 2016-09-03.
What conditions does trial NCT02355743 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT02355743?
The interventions under investigation include: rtPA lock therapy (DRUG).
Who is sponsoring clinical trial NCT02355743?
This trial is sponsored by Lynn Malec, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02355743 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
RECRUITING · NA
-
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
RECRUITING · Early Phase 1
-
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
RECRUITING · Phase 2
-
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
RECRUITING · NA
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Registry for Participants With Short Bowel Syndrome
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.